These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 33316266)

  • 1. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors.
    P KM; Sivashanmugam K; Kandasamy M; Subbiah R; Ravikumar V
    Life Sci; 2021 Feb; 266():118883. PubMed ID: 33316266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis.
    Vaz de Paula CB; Nagashima S; Liberalesso V; Collete M; da Silva FPG; Oricil AGG; Barbosa GS; da Silva GVC; Wiedmer DB; da Silva Dezidério F; Noronha L
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healing after COVID-19: are survivors at risk for pulmonary fibrosis?
    McDonald LT
    Am J Physiol Lung Cell Mol Physiol; 2021 Feb; 320(2):L257-L265. PubMed ID: 33355522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
    Pitt B; Sutton NR; Wang Z; Goonewardena SN; Holinstat M
    Eur J Pharmacol; 2021 May; 898():173988. PubMed ID: 33667455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis.
    Venkataraman T; Frieman MB
    Antiviral Res; 2017 Jul; 143():142-150. PubMed ID: 28390872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapeutic options for coronavirus disease 2019 (COVID-19)-lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol.
    Zhang ZL; Zhong H; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
    Ann Transl Med; 2020 Nov; 8(22):1527. PubMed ID: 33313272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.
    Zhang C; Wu Z; Li JW; Tan K; Yang W; Zhao H; Wang GQ
    J Med Virol; 2021 Mar; 93(3):1378-1386. PubMed ID: 33107641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19: from an acute to chronic disease? Potential long-term health consequences.
    Higgins V; Sohaei D; Diamandis EP; Prassas I
    Crit Rev Clin Lab Sci; 2021 Aug; 58(5):297-310. PubMed ID: 33347790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts.
    John AE; Joseph C; Jenkins G; Tatler AL
    Immunol Rev; 2021 Jul; 302(1):228-240. PubMed ID: 34028807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), influenza, and COVID-19, beyond the lungs: a review article.
    Lombardi AF; Afsahi AM; Gupta A; Gholamrezanezhad A
    Radiol Med; 2021 Apr; 126(4):561-569. PubMed ID: 33242204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS.
    Fathi M; Vakili K; Deravi N; Yaghoobpoor S; Ahsan E; Mokhtari M; Moshfeghi M; Vaezjalali M
    Przegl Epidemiol; 2020; 74(2):276-289. PubMed ID: 33112124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.
    Cashman DP
    Med Hypotheses; 2020 Nov; 144():110027. PubMed ID: 32758873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 patients may become predisposed to pulmonary arterial hypertension.
    Suzuki YJ; Nikolaienko SI; Shults NV; Gychka SG
    Med Hypotheses; 2021 Feb; 147():110483. PubMed ID: 33444904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
    Hamidi SH; Kadamboor Veethil S; Hamidi SH
    Pharmacol Rep; 2021 Jun; 73(3):712-727. PubMed ID: 33880743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.